SecBot SecBot
8-K ·Filed Aug 17, 2026

NRXP

NRX Pharmaceuticals, Inc.
BULLISH
Impact 7/10
Horizonweeks Processed3mo ago SEC0001437749-26-028111
8-K Item 2.02: Earnings release
Actionable Insight ▲ Bullish

The FDA ANDA review nearing completion with only a vial attestation remaining is the most near-term catalyst, approval and commercial launch could transform the company from pre-revenue to revenue-generating. Monitor for FDA decision on the ANDA and any updates on the DARPA contract finalization, as these represent the primary value drivers over the next 3-6 months.

DirectionBullish
Confidencehigh
Horizonweeks

Preservative-Free Ketamine

◆ Mixed Named in this 8-K
Impact
Phase
Approved (ANDA)
Time to market
Approved as of October 30, 2026. The company has ordered 5 million vials for launch inventory and is transitioning to commercial-stage operations.
Next catalyst
None dated

What to watchThe ANDA approval binary has passed. Watch for commercial launch execution (hospital formulary adoption, initial sales numbers) and the Q3 2026 earnings call on November 16 for revenue guidance. The bigger binary catalyst ahead is the NRX-100 NDA decision for suicidal depression (estimated PDUFA ~December 2026), which targets a much larger market opportunity than the generic ANDA product. Also monitor the FDA's decision on NRx's citizen petition to ban BZT-containing ketamine products, which could dramatically alter the competitive landscape.

How the stock moved after the report

⚠ Clustered BULLISH VIEWSTOCK BELOW ENTRY AT T+60
Entry
$3.43
T+0 close · Aug 17, 2026 · via day close
Latest settled
−30.61%
T+60 · $2.38
Vs SPY
−27.85%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Aug 17 $3.43entry
  2. T+1 · 3mo ago +0.29%α +0.97% · $3.44
  3. T+5 · 3mo ago +0.58%α +1.77% · $3.45
  4. T+20 · 2mo ago +1.75%α +3.28% · $3.49
  5. T+60 · 7d ago −30.61%α −27.85% · $2.38

Price Chart

Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

NRx Pharmaceuticals reported Q2 2026 financial results with a net loss of $18.0M for the six months ended June 30, 2026, compared to a $23.1M loss in the prior-year period. The company highlighted key regulatory progress on its ANDA for preservative-free ketamine, a DARPA contract for NRX-101, and a strengthened cash position of $26.7M following a $22.3M public offering, extending its cash runway to at least one year. The filing is bullish due to the tangible regulatory and funding milestones, though the company remains pre-revenue with operating losses widening.

Key Facts

  • Completed first-cycle FDA review of ANDA for preservative-free ketamine with no drug-related major deficiencies; sole remaining item (manufacturer's attestation) submitted.
  • Selected by DARPA as prime contractor for SPARC-TMS trial of NRX-101 with robotic TMS; anticipated non-dilutive funding exceeds $11.5 million.
  • Closed institutionally-supported underwritten public offering for gross proceeds of $22.3 million, including full exercise of underwriters' option.
  • Cash and cash equivalents of $26.7 million as of June 30, 2026, up from $7.8 million at December 31, 2025.
  • Net loss for six months ended June 30, 2026 was $18.0 million vs $23.1 million in prior-year period; net operating loss was $11.3 million vs $7.6 million.
  • Appointed Glenn Tyson as first Chief Commercial Officer and retained commercial launch team for preservative-free ketamine.
  • HOPE Therapeutics expanded clinical footprint with new sites in Florida and became first US commercial site to use Zeta Surgical's FDA-cleared TMS navigation system.

Financial Impact

Cash balance increased by $18.9M from year-end 2025 to $26.7M; net loss improved by $5.1M vs prior-year six-month period; operating loss widened by $3.7M due to R&D and commercial launch costs.

cashnet lossoperating lossresearch and development costsselling, general and administrative costs

Risk Factors

  • ANDA approval is not guaranteed; FDA could still issue additional deficiencies or reject the application.
  • Company remains pre-revenue with widening operating losses; cash runway depends on successful commercialization and potential further dilution via the at-the-market offering facility.
  • DARPA funding is subject to completion of contracting and may not materialize as anticipated.
  • NRX-100 NDA and NRX-101 Phase 2/3 trial are years away from potential approval; clinical failure risk is significant.

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
91% bullish (11 analysts)

Investment Themes

Documents Analyzed

This report is based on 6 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001437749-26-028111
Exhibit: ex_1005774.htm0001437749-26-028111
Document: 0001437749-26-028111-index-headers.html0001437749-26-028111
Document: 0001437749-26-028111-index.html0001437749-26-028111
Document: 0001437749-26-028111.txt0001437749-26-028111
8-K Data (Synthetic)0001437749-26-028111

Track record

22 reports on NRXP

Performance horizon

7 of 12 bullish or bearish reports moved the stock their way by T+5. Best: +70.33% at T+60 after the Mar 30, 2026 report. 9 of 12 went positive at some point.

Filters
  1. Nov 5, 202611d ago DEFA14A Neutral 3/10 Entry $2.38 to $2.19 Now $2.15 −9.66% ▼ −7.98% −10.58% vs SPY
  2. Nov 5, 202611d ago DEF 14A Neutral 4/10 Entry $2.38 to $2.19 Now $2.15 −9.66% ▼ −7.98% −10.58% vs SPY
  3. Nov 2, 202614d ago 8-K Bullish 6/10 Entry $2.17 to $2.38 Now $2.15 −0.92% ▲ +9.68% +9.60% vs SPY
  4. Oct 30, 202617d ago Press Release Bullish 7/10 Entry $2.27 to $2.38 Now $2.15 −5.29% ▲ +4.85% +7.55% vs SPY
  5. Oct 16, 20264w ago 8-K Neutral 2/10 Entry $2.63 to $2.52 Now $2.15 −18.25% ▼ −4.18% −4.04% vs SPY
  6. Oct 5, 20266w ago 8-K Bullish 6/10 Entry $2.94 to $2.70 Now $2.15 −26.87% ▼ −8.16% −8.02% vs SPY
  7. Sep 15, 20268w ago 8-K Bullish 5/10 Entry $3.35 to $3.16 Now $2.15 −35.82% ▼ −5.67% −8.24% vs SPY
  8. Sep 14, 20269w ago 8-K Neutral 2/10 Entry $3.49 to $3.29 Now $2.15 −38.40% ▼ −5.73% −5.84% vs SPY
  9. Aug 17, 202613w ago 8-K Bullish 7/10 Viewing Entry $3.43 to $3.45 Now $2.15 −37.32% ▲ +0.58% +1.77% vs SPY
  10. Aug 17, 202613w ago Press Release Neutral 1/10 Entry $3.43 Now $2.15 −37.32% No price data
Showing 10 of 22

US Market Status

Market Closed · Opens in 6h 34m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Aug 17, 2026